Durvalumab + Tremelimumab + Enfortumab Vedotin
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Muscle Invasive Bladder Cancer
Conditions
Muscle Invasive Bladder Cancer
Trial Timeline
Aug 5, 2021 → Sep 8, 2028
NCT ID
NCT04960709About Durvalumab + Tremelimumab + Enfortumab Vedotin
Durvalumab + Tremelimumab + Enfortumab Vedotin is a phase 3 stage product being developed by AstraZeneca for Muscle Invasive Bladder Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04960709. Target conditions include Muscle Invasive Bladder Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04960709 | Phase 3 | Active |
Competing Products
20 competing products in Muscle Invasive Bladder Cancer